Pearson Injunction Against FDA Denied By Federal Judge
This article was originally published in The Tan Sheet
Executive Summary
A preliminary injunction against FDA requested by the Pearson v. Shalala plaintiffs was denied May 24 by D.C. federal court judge Gladys Kessler. An appeal was filed May 26 by Emord & Associates (Washington, D.C.).
You may also be interested in...
Supplement Health Claim Approval Costs Unaffordable, Economist Says
Dietary supplement companies would have to spend between $58 mil. and $348 mil. for NDA-type approval for each of six health claims they seek to make under FDA's significant scientific agreement standard, an Emory University economist maintains.
Supplement Health Claim Approval Costs Unaffordable, Economist Says
Dietary supplement companies would have to spend between $58 mil. and $348 mil. for NDA-type approval for each of six health claims they seek to make under FDA's significant scientific agreement standard, an Emory University economist maintains.
Supplement Health Claim Approval Costs Unaffordable, Economist Says
Dietary supplement companies would have to spend between $58 mil. and $348 mil. for NDA-type approval for each of six health claims they seek to make under FDA's significant scientific agreement standard, an Emory University economist maintains.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: